This study evaluated toxicities in breast cancer patients receiving chemotherapy. Patients who received 6 cycles of CMF chemotherapy showed low red blood cell, white blood cell and platelet counts, as well as elevated liver enzymes and lactate dehydrogenase, compared to newly diagnosed patients who did not receive chemotherapy. Patients who received both CMF and tamoxifen had higher red blood cell counts and lower alkaline phosphatase levels than those who only received CMF.

1. Evaluation of toxicities induced by chemotherapy in breast cancer
patients.
(PMID:16154313)

Abstract

Citations

BioEntities

Related Articles

External Links
Mehreen L ,
Khanam A
Department of Biochemistry, University of Karachi, Karachi 75270, Pakistan.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie [2005, 59(9):524-527]
Type: Clinical Trial, Journal Article, Comparative Study
DOI: 10.1016/j.biopha.2004.12.002
Abstract
The study includes the breast cancer female patients who had received chemotherapy
(CMF, tamoxifen) and the newly diagnosed breast cancer patients, who had not
received any chemotherapy. The patients who had received six cycles of CMF had
shown low RBC, WBC and platelet count, elevated levels of SGPT, alkaline
phosphatase and lactatedehydrogenase as compared to newly diagnosed
breast cancer patients. The RBC count is increased in patients who had received CMF
and tamoxifen as compared to the patients received only CMF, the alkaline
phosphatase level is also declined in patients who had received CMF and tamoxifen as
compared to the patients received CMF only.